Maxim Shevtsov MD, DO, PhD

Dr. Maxim A. Shevtsov, Ph.D., currently holds a postdoctoral position at Klinikum rechts der Isar, Technische Universität München, Department of Radiation Oncology (Munich, Germany). He got his B Sc and M Sc in medicine from I.P. Pavlov State Medical University of St. Petersburg (Russia) and is a specialist in neuro-surgery at A.L. Polenov Russia Research Scientific Institution of Neurosurgery (St. Petersburg, Russia). He did his PhD thesis at the Institute of Cytology of the Russian Academy of Sciences (RAS) (St.Petersburg, Russia) under the supervision of Dr.Sci. Boris Margulis.

One of the focus areas of the research work of Dr. Maxim Shevtsov is the development of innovative immunotherapeutic methods based on the application of recombinant protein Hsp70 or its inhibitors in oncology. The aim is to use these novel therapeutic approaches in combination with conventional therapies in the treatment of malignant brain tumors in translational and clinical trials. Dr. Shevtsov’s research interests also include the analysis of magnetic nanoparticles in the diagnostics and therapy of malignant brain tumors. He is a member of numerous professional and scientific associations, including AACR (American Association of Cancer Research), EANO (European Association of Neuro-Oncology), EACR (The European Association for Cancer Research), SITC (Society for Immunotherapy of Cancer), EANS (European Association of Neurosurgeons). He was awarded the prestigious Alexander von Humboldt Fellowship (2016), Yamagiwa-Yoshida Memorial International Cancer Study Grant (2014), and Codman Fellowship (2014).

As part of international activities, Dr. Shevtsov established collaborations with the University College of London, Cancer Institute (UK, Prof. K.Chester), School of Biotechnology, KIIT University (India, Prof. A. Sonawane), West China School of Pharmacy, Sichuan University (China, Associate Prof. H. Gao).